Long QTc in hypertrophic cardiomyopathy: A consequence of structural myocardial damage or a distinct genetic disease?
LQTS
QTc
QTc abnormalities
gene muatation
hypertrophic cardiomyopathy
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2023
2023
Historique:
received:
30
11
2022
accepted:
01
03
2023
medline:
24
4
2023
pubmed:
24
4
2023
entrez:
24
04
2023
Statut:
epublish
Résumé
Hypertrophic cardiomyopathy (HCM) is an autosomal dominant disease, characterized by the presence of unexplained left ventricular hypertrophy. This condition is often associated with electrocardiographic abnormalities including QTc prolongation occurring in 13% of patients. The main explanation for prolonged QTc in HCM is myocardial hypertrophy and the related structural damage. However, other mechanisms, including long QT syndrome (LQTS) genes mutations, may be involved. In the present study we explored the hypothesis of a distinct genetic basis underlying QTc prolongation in HCM by investigating the potential co-inheritance of pathogenic gene variants associated with LQTS and HCM. For this purpose, starting from a cohort of 150 HCM patients carrying pathogenic variants in sarcomere genes, we selected 25 patients carrying a QTc prolongation unexplained by any other cause. The QTc was considered prolonged if greater than 450 ms in males and greater than 470 ms in females. The NGS analysis was performed with Illumina TrueSight Cardio panel genes on Illumina MiniSeq platform. We identified pathogenic/likely pathogenic variants in the
Identifiants
pubmed: 37089884
doi: 10.3389/fcvm.2023.1112759
pmc: PMC10113437
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1112759Informations de copyright
© 2023 Cava, Micolonghi, Musumeci, Petrucci, Savio, Fabiani, Tini, Germani, Libi, Rossi, Visco, Pizzuti, Volpe, Autore, Rubattu and Piane.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Cardiovasc Med. 2016 Jun 27;3:20
pubmed: 27446933
Circ Res. 2017 Sep 15;121(7):749-770
pubmed: 28912181
J Mol Cell Cardiol. 2001 Feb;33(2):219-31
pubmed: 11162128
Eur Heart J. 2010 Feb;31(4):439-49
pubmed: 19897498
J Am Coll Cardiol. 2010 Jun 15;55(24):2745-52
pubmed: 20538168
Medicina (Kaunas). 2019 Jun 23;55(6):
pubmed: 31234582
J Electrocardiol. 2014 Sep-Oct;47(5):642-8
pubmed: 24813353
Prog Biophys Mol Biol. 2008 Oct-Nov;98(2-3):219-29
pubmed: 19027779
Europace. 2016 Apr;18(4):602-9
pubmed: 25825456
Mol Genet Metab Rep. 2021 Mar 18;27:100743
pubmed: 33777698
Kardiol Pol. 2014;72(11):1054-126
pubmed: 25524376
Open Heart. 2017 Oct 21;4(2):e000658
pubmed: 29118996
Circulation. 1992 Aug;86(2):345-52
pubmed: 1638703
Circ Genom Precis Med. 2018 Oct;11(10):e002255
pubmed: 30354306
J Cardiol. 2017 Oct;70(4):310-315
pubmed: 28341542
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
J Arrhythm. 2017 Jun;33(3):201-207
pubmed: 28607615
Eur Heart J. 2011 May;32(9):1114-20
pubmed: 21345853
JAMA Cardiol. 2022 Sep 1;7(9):966-974
pubmed: 35947370
J Cardiovasc Pharmacol. 2002 Jun;39(6):866-74
pubmed: 12021581
Br J Sports Med. 2009 Sep;43(9):657-62
pubmed: 19734499
Hum Mutat. 2009 Nov;30(11):1486-511
pubmed: 19862833
Circ Cardiovasc Genet. 2009 Apr;2(2):182-90
pubmed: 20031583
Heart. 2003 Aug;89(8):882-6
pubmed: 12860864